Witnessing the stock’s movement on the chart, on Wednesday, Heron Therapeutics Inc (NASDAQ: HRTX) set off with pace as it heaved 1.69% to $1.80, before settling in for the price of $1.77 at the close. Taking a more long-term approach, HRTX posted a 52-week range of $0.50-$3.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 17.85%. Meanwhile, its Annual Earning per share during the time was 20.01%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 84.19%. This publicly-traded company’s shares outstanding now amounts to $150.29 million, simultaneously with a float of $144.07 million. The organization now has a market capitalization sitting at $273.00 million. At the time of writing, stock’s 50-day Moving Average stood at $1.8918, while the 200-day Moving Average is $2.6034.
Heron Therapeutics Inc (HRTX) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Heron Therapeutics Inc’s current insider ownership accounts for 5.01%, in contrast to 81.10% institutional ownership. According to the most recent insider trade that took place on Nov 17 ’23, this organization’s EVP, Chief Development Officer bought 25,000 shares at the rate of 1.09, making the entire transaction reach 27,250 in total value, affecting insider ownership by 79,000. Preceding that transaction, on Nov 16 ’23, Company’s EVP, Chief Development Officer bought 50,000 for 0.94, making the whole transaction’s value amount to 46,995. This particular insider is now the holder of 54,000 in total.
Heron Therapeutics Inc (HRTX) Earnings and Revenue Records
Heron Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 84.19% and is forecasted to reach -0.02 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 47.50% through the next 5 years, which can be compared against the 20.01% growth it accomplished over the previous five years trading on the market.
Heron Therapeutics Inc (NASDAQ: HRTX) Trading Performance Indicators
Let’s observe the current performance indicators for Heron Therapeutics Inc (HRTX). It’s Quick Ratio in the last reported quarter now stands at 1.85. The Stock has managed to achieve an average true range (ATR) of 0.12. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.00.
In the same vein, HRTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.33, a figure that is expected to reach -0.04 in the next quarter, and analysts are predicting that it will be -0.02 at the market close of one year from today.
Technical Analysis of Heron Therapeutics Inc (HRTX)
Going through the that latest performance of [Heron Therapeutics Inc, HRTX]. Its last 5-days volume of 1.65 million was inferior to the volume of 2.43 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 42.94% While, its Average True Range was 0.1222.
Raw Stochastic average of Heron Therapeutics Inc (HRTX) in the period of the previous 100 days is set at 14.80%, which indicates a major fall in contrast to 65.49% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 50.40% that was lower than 85.55% volatility it exhibited in the past 100-days period.
